Compare Schlumberger NV (SLB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs BIO-TECHNE Corp — how do they compare? Schlumberger NV trades at $57.14 (market cap $84.74B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Schlumberger NV is far larger — about 7.5× BIO-TECHNE Corp's market cap, and Schlumberger NV pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| SLB | TECH | |
|---|---|---|
Market Cap | $84.74B | $11.34B |
Sector | Energy | Health |
52-Week High | $60.10 | $72.48 |
52-Week Low | $31.72 | $43.31 |
Enterprise Value | $93.47B | $11.36B |
Dividend Yield | 2.07% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $57.10, down 0.71% on the day, but remains near recent highs with a bullish technical trend. The company reported three consecutive quarterly earnings beats, with Q3 2026 expected at $0.62 EPS. Recent news highlights the $3.4 billion acquisition of Kelvion, expanding SLB's data center cooling business. Revenue for 2025 was $35.71 billion with a net income margin of 8.53%, though margins have softened from prior years. Analyst consensus is strongly bullish with an average price target of $63.00.
The outlook for SLB is positive, driven by strategic diversification into data centers and solid operational cash flow near $6.5 billion annually. Key risks include exposure to oil price volatility and integration challenges from the Kelvion deal. With 85% of analysts rating it a buy, the stock offers upside potential but requires monitoring of execution on new growth initiatives.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
